Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial.

Moon, Kyunglan; Hong, Kyung-Wook; Bae, In-Gyu

Moon, Kyunglan; Hong, Kyung-Wook; Bae, In-Gyu.

Afiliación

Moon K; Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Republic of Korea.
Hong KW; Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Republic of Korea.
Bae IG; Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Republic of Korea. ttezebae@gmail.com.

Trials ; 22(1): 832, 2021 Nov 23.

Article en En | MEDLINE | ID: mdl-34814935

Asunto(s)

COVID-19; Benzamidinas; Guanidinas/efectos adversos; Humanos; Hidroxicloroquina; Ensayos Clínicos Controlados Aleatorios como Asunto; SARS-CoV-2; Resultado del Tratamiento

Palabras clave

COVID-19; Nafamostat mesilate; Randomized controlled trial; Time to improvement; protocol

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google